On the contrary, early results from the Phase 3 MAGNITUDE study assessing the combination of niraparib and abiraterone in a similar patient population revealed a significant benefit with the combination of niraparib and abiraterone in patients with BRCA1/2-mutated or HRR-mutated cancer (defined as ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2 mutations), but not HRR-negative prostate cancer [124]. This evidence concerns the gene BRCA1 and cancer.